List of Excipients in Branded Drug ABSTRAL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sentynl Therapeutics Inc	ABSTRAL	fentanyl citrate	42358-100	CELLULOSE, MICROCRYSTALLINE
Sentynl Therapeutics Inc	ABSTRAL	fentanyl citrate	42358-100	CROSCARMELLOSE SODIUM
Sentynl Therapeutics Inc	ABSTRAL	fentanyl citrate	42358-100	MAGNESIUM STEARATE
Sentynl Therapeutics Inc	ABSTRAL	fentanyl citrate	42358-100	MANNITOL
ProStrakan Inc	ABSTRAL	fentanyl	42747-221	CELLULOSE, MICROCRYSTALLINE
ProStrakan Inc	ABSTRAL	fentanyl	42747-221	CROSCARMELLOSE SODIUM

ABSTRAL Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 9, 2026

ABSTRAL is a fentanyl citrate sublingual tablet designed for rapid transmucosal delivery in opioid-tolerant adults with breakthrough cancer pain. Its commercial value is tied less to novel active-ingredient chemistry than to dose uniformity, rapid disintegration, taste control, moisture stability, child-resistant packaging, and regulatory control of fentanyl products.

The core excipient opportunity is to improve the sublingual delivery platform without changing the approved dosage-form profile. The most attractive targets are co-processed excipients, low-moisture formulations, taste-masking systems, and manufacturing controls that reduce variability across the 100 to 800 microgram strength range.

What is ABSTRAL and how does its formulation work?

ABSTRAL contains fentanyl citrate in sublingual tablets available in 100, 200, 300, 400, 600, and 800 microgram strengths. The tablet is placed under the tongue, where it rapidly disintegrates and delivers fentanyl through the oral mucosa. The product is indicated for breakthrough cancer pain in patients already receiving opioid maintenance therapy and who are opioid tolerant.[1]

The formulation uses conventional pharmaceutical excipients rather than a complex polymeric or device-based delivery system. Public product information identifies the principal excipient classes as:

Excipient or excipient class	Likely formulation role
Mannitol	Diluent, mouthfeel modifier, water-soluble filler
Microcrystalline cellulose	Compressibility and tablet structure
Croscarmellose sodium	Rapid swelling and disintegration
Magnesium stearate	Lubrication during tableting

The low fentanyl dose creates a significant content-uniformity challenge. Most of the tablet mass consists of excipients, while the active ingredient is present at microgram scale. Manufacturing must control blending, segregation, compression, assay, dissolution, and tablet-to-tablet dose variation.

What excipients protect ABSTRAL’s commercial performance?

ABSTRAL’s excipient strategy supports four performance requirements: fast tablet breakup, acceptable sublingual feel, dose uniformity, and stability.

Rapid disintegration

Croscarmellose sodium is a high-value component because the dosage form depends on rapid tablet disintegration in a limited volume of saliva. The excipient must provide fast liquid uptake without producing a bulky or gritty residue.

Commercial opportunities include:

• Superdisintegrant grades optimized for direct compression.
• Co-processed mannitol-disintegrant systems.
• Porous fillers that increase saliva penetration.
• Low-force compression systems that preserve tablet porosity.
• Excipient combinations that maintain disintegration at higher strengths.

A replacement excipient would need to demonstrate equivalent or superior disintegration without increasing friability, sticking, or dose segregation.

Mouthfeel and palatability

Fentanyl is pharmacologically potent, but sublingual products remain exposed to taste perception during tablet breakup. Mannitol is commercially important because it provides a relatively clean mouthfeel and cooling sensation compared with some alternative fillers.

Potential improvements include:

• Direct-compression mannitol with controlled particle size.
• Taste-masking coatings applied to excipient or active particles.
• Ion-exchange or complexation approaches that reduce immediate fentanyl bitterness.
• Low-sugar polyols for patients requiring reduced sucrose exposure.
• Flavors compatible with a very small tablet and rapid mucosal absorption.

Taste masking must not delay fentanyl release or increase swallowing. A coating that shifts delivery from the sublingual mucosa to the gastrointestinal tract could undermine the product’s pharmacokinetic profile.

Dose uniformity

The most important technical risk is segregation of fentanyl citrate during blending and tableting. The active ingredient is present in very small quantities, so particle size, density, electrostatic behavior, and surface adhesion matter.

High-value excipient strategies include:

1. Ordered mixing, in which fentanyl particles adhere to carrier particles.
2. Spray-dried or granulated active-excipient intermediates.
3. Co-processed fillers with a narrow particle-size distribution.
4. Low-shear blending that limits demixing.
5. Excipient surface modification to improve fentanyl distribution.
6. In-process near-infrared monitoring of blend uniformity.

A commercial supplier that can provide a validated, low-segregation excipient platform may capture value through a formulation license, preferred-supplier arrangement, or technology transfer.

Moisture management

Sublingual tablets must disintegrate rapidly in saliva but remain physically stable during storage. Moisture can affect tablet hardness, disintegration, fentanyl stability, and excipient performance.

The packaging system is therefore part of the commercial formulation strategy. Relevant options include:

• High-barrier aluminum blister packs.
• Unit-dose packaging with low water-vapor transmission.
• Desiccant-assisted secondary packaging.
• Child-resistant blister systems.
• Packaging designed for controlled-substance distribution and dose accountability.

A moisture-sensitive formulation may support a differentiated packaging patent even where the tablet composition uses established excipients.

What formulations are protected by ABSTRAL-related intellectual property?

ABSTRAL’s protectable value is likely concentrated in formulation and manufacturing claims rather than fentanyl’s active pharmaceutical ingredient. Fentanyl and fentanyl citrate are longstanding compounds, and the commercial differentiation comes from the dosage form, release behavior, strength range, and manufacturing process.

Potential claim categories include:

Claim category	Commercial relevance
Sublingual fentanyl tablet composition	Protects the combination of fentanyl citrate and excipient classes
Rapid-disintegration profile	Links composition to a defined in vitro or in vivo performance
Dose-strength architecture	Covers multiple microgram strengths made through a common platform
Content-uniformity process	Protects blending, granulation, or ordered-mixing steps
Taste-masking system	May protect coating, complexation, or particle engineering
Moisture-protective package	Covers blister materials or storage configuration
Method of treating breakthrough cancer pain	May provide method-of-use protection where listed and enforceable

An exact, current patent-expiration analysis requires the relevant Orange Book entries, patent certifications, terminal disclaimers, pediatric extensions, and litigation history for the applicable jurisdiction. The FDA identifies ABSTRAL under NDA 022510 in its product database, while the approved label is the primary source for the dosage form, strengths, indication, and safety controls.[1,2]

When does ABSTRAL lose exclusivity?

ABSTRAL’s regulatory exclusivity and patent exclusivity are separate.

FDA approval of ABSTRAL occurred in 2011. New-drug exclusivity associated with the original approval has expired. Any remaining market protection would depend on active patents, pediatric exclusivity, regulatory restrictions, product discontinuation status, and the ability of an abbreviated new drug application applicant to satisfy fentanyl-specific safety requirements.

The relevant U.S. entry pathway is an ANDA for a generic fentanyl sublingual tablet. A generic applicant would need to address:

• Pharmaceutical equivalence.
• Bioequivalence or an FDA-accepted alternative endpoint.
• Dosage-form performance.
• Controlled-substance requirements.
• Labeling and risk-management obligations.
• Any listed patents through Paragraph IV certification or another statutory pathway.

For Europe and other markets, the timing depends on national patent rights, supplementary protection certificate status where applicable, national authorization history, and local controlled-drug rules.

What is the Orange Book status of ABSTRAL?

The FDA Orange Book is the controlling source for listed patents and exclusivity associated with an approved U.S. drug product. ABSTRAL is associated with NDA 022510 in FDA materials.[2]

For commercial diligence, the Orange Book review should distinguish:

• Active ingredient patents.
• Drug-product or formulation patents.
• Method-of-use patents.
• Delisted patents.
• Patent expiration dates.
• Paragraph IV certifications.
• First-filer events.
• 30-month litigation stays.
• Any changes caused by patent-listing disputes.

Because fentanyl sublingual products carry substantial safety controls, an Orange Book clearance does not by itself guarantee rapid generic launch. Manufacturing controls, controlled-substance registration, supply-chain security, and regulatory review can remain meaningful barriers.

Which companies are challenging ABSTRAL?

Publicly available FDA materials identify the reference product and its NDA, but a challenge assessment must separate three categories:

1. ANDA applicants that have filed Paragraph IV certifications.
2. Applicants pursuing non-infringing or later-entry pathways.
3. Companies developing alternative fentanyl products rather than direct ABSTRAL substitutes.

A direct generic challenge would be more commercially relevant than competition from fentanyl lozenges, buccal tablets, nasal sprays, or transdermal systems. These products may compete for the same breakthrough-pain population but are not automatically substitutable at the pharmacy level.

The principal competitive groups are:

• Generic pharmaceutical companies with controlled-substance infrastructure.
• Specialty manufacturers with opioid product portfolios.
• Companies commercializing alternative transmucosal fentanyl systems.
• Contract manufacturers capable of high-potency, low-dose tablet production.
• Excipient suppliers with direct-compression and taste-masking platforms.

How strong is the ABSTRAL patent estate?

The patent estate should be assessed as a formulation-and-execution estate rather than an active-ingredient estate.

Strengths

• Fentanyl sublingual delivery can support composition and performance claims.
• Low-dose content uniformity creates manufacturing complexity.
• Rapid disintegration and transmucosal delivery can provide meaningful product-specific differentiation.
• Packaging and controlled-substance handling may create practical barriers beyond formal patent scope.

Weaknesses

• Fentanyl is an established active ingredient.
• Sublingual and transmucosal delivery are established dosage-form concepts.
• Many candidate excipients are pharmacopeial and widely used.
• Generic applicants may design around narrow excipient claims.
• A tablet composition based only on conventional excipients may face obviousness and enablement challenges if claim scope is broad.

The strongest surviving claims would likely be those tied to a specific combination of composition, disintegration, pharmacokinetic performance, dose uniformity, or manufacturing process. Broad claims covering fentanyl plus standard tableting excipients are more vulnerable to prior-art and obviousness challenges.

What generic entry risks exist for ABSTRAL?

Generic entry risk is substantial after the expiration of enforceable product patents, but the commercial risk is moderated by the product’s safety profile and limited patient population.

Regulatory barriers

Fentanyl is a controlled substance with a high risk of misuse, abuse, accidental exposure, and fatal overdose. FDA labeling requires restricted distribution and risk-management controls for transmucosal immediate-release fentanyl products. The TIRF REMS applies to products in this category and is intended to limit use to appropriate patients and prescribers.[3]

A generic applicant must manage:

• Drug Enforcement Administration registration.
• Controlled-substance quotas.
• Secure manufacturing and distribution.
• Diversion controls.
• REMS implementation.
• Pharmacovigilance.
• Packaging and labeling controls.

Commercial barriers

ABSTRAL addresses a narrow indication and requires opioid-tolerant patients. Market expansion is constrained by:

• Specialist prescribing.
• Oncology and palliative-care concentration.
• High safety scrutiny.
• Patient titration requirements.
• Product-specific dosing limits.
• Restricted distribution.
• Competition from other rapid-onset fentanyl products.

A generic manufacturer may launch with a discount but still face limited volume. The most credible launch scenario is a small number of controlled-substance specialists entering after patent clearance, followed by price erosion and formulary substitution.

What excipient opportunities exist for ABSTRAL generics?

The strongest opportunities are not commodity substitution. They are performance improvements that reduce manufacturing cost or regulatory risk.

Co-processed excipients

A co-processed filler-disintegrant system could improve flow, compressibility, and blend uniformity. The commercial proposition is strongest if the platform:

• Reduces blending time.
• Prevents active segregation.
• Supports direct compression.
• Preserves rapid disintegration.
• Works across all six strength levels.
• Reduces tablet weight or packaging volume.

Taste-masking technology

Taste masking could create a differentiated product, but it must preserve rapid sublingual release. Potential technologies include microencapsulation, ion pairing, polymeric coating, and cyclodextrin complexation. These approaches require careful control because fentanyl absorption, not merely tablet breakup, drives product performance.

Low-moisture formulations

An excipient system with lower hygroscopicity could reduce dependence on high-barrier packaging. The value would come from lower packaging cost, longer in-use stability, and reduced tablet variability in humid markets.

Manufacturing licenses

A platform that delivers consistent microgram-dose distribution could be licensed to generic manufacturers. The licensor could charge an upfront fee, milestone payments, royalties, or supply the proprietary co-processed excipient.

Packaging and adherence systems

Unit-dose, child-resistant, tamper-evident packaging has commercial value in controlled-substance products. Packaging companies can pursue supply agreements with manufacturers even where the tablet composition remains conventional.

How does ABSTRAL compare with other fentanyl dosage forms?

Product type	Main delivery route	Commercial distinction	Excipient opportunity
ABSTRAL	Sublingual tablet	Rapid tablet disintegration and transmucosal delivery	Taste, disintegration, content uniformity
Buccal tablet	Buccal mucosa	Adhesion and controlled mucosal residence	Mucoadhesive polymers
Buccal film	Buccal mucosa	Flexible dose delivery and adhesion	Film-forming polymers and plasticizers
Nasal spray	Nasal mucosa	Rapid administration and no tablet handling	Viscosity modifiers and spray-device compatibility
Oral transmucosal lozenge	Buccal/oral cavity	Extended contact time	Sweeteners, binders, and lozenge structure
Transdermal patch	Skin	Long-duration systemic delivery	Pressure-sensitive adhesive and permeation enhancers

ABSTRAL’s strongest competitive position is convenience for patients who need a small, rapidly disintegrating tablet without a device. Its main weakness is the limited therapeutic population and the safety burden associated with immediate-release fentanyl.

What licensing deals and partnerships are relevant?

ABSTRAL was developed and commercialized through the specialty pharmaceutical sector, with ProStrakan associated with the product’s U.S. development and Kyowa Kirin later acquiring ProStrakan.[4] The commercial model illustrates the value of regional licensing and specialty distribution for controlled oncology products.

The most plausible future partnership structures involve:

• Regional commercialization licenses.
• Generic development and supply agreements.
• Co-processed excipient licenses.
• Contract manufacturing for high-potency tablets.
• Packaging and serialization agreements.
• Rights to alternative transmucosal formulations.

An excipient company is more likely to obtain value through a formulation-development partnership than through standalone sale of mannitol, cellulose, or magnesium stearate. The commercial moat must come from validated performance, regulatory documentation, and manufacturing reproducibility.

What FDA regulatory status affects ABSTRAL commercialization?

ABSTRAL’s FDA-approved indication is limited to breakthrough cancer pain in opioid-tolerant adults.[1] The label carries major warnings concerning respiratory depression, medication errors, accidental ingestion, and misuse. The TIRF REMS framework affects prescriber, pharmacy, patient, and distributor operations.[3]

These controls influence excipient commercialization in two ways:

1. Any formulation change must preserve the approved product’s performance and safety profile.
2. A differentiated product cannot assume broad consumer or primary-care adoption.

A new excipient system that changes absorption, peak concentration, onset, or exposure could require substantial comparative evidence. A change limited to inactive ingredients may still require full pharmaceutical-development and regulatory justification if it affects bioavailability or product performance.

What are the key commercial opportunities?

The highest-value opportunities rank as follows:

Opportunity	Value potential	Main barrier
Co-processed excipient for dose uniformity	High	Demonstrating reproducibility at microgram dose
Taste-masked sublingual system	High	Preserving rapid transmucosal absorption
Low-moisture direct-compression platform	Medium-high	Stability and packaging validation
Child-resistant unit-dose packaging	Medium	Human factors and controlled-substance compliance
Generic formulation development services	Medium-high	Patent and ANDA timing
Commodity excipient substitution	Low	Limited differentiation and price pressure
New pediatric or broader-pain indication	Low	Fentanyl safety and regulatory restrictions

Revenue exposure is difficult to isolate because ABSTRAL sales are generally reported within broader specialty pharmaceutical or oncology portfolios rather than as a standalone public segment. Commercial diligence should therefore focus on prescription volume, payer substitution, net price, restricted-distribution economics, and the number of active competitors rather than headline fentanyl-market size.

Key Takeaways

• ABSTRAL’s central formulation challenge is uniform delivery of microgram quantities of fentanyl citrate.
• Mannitol, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate support the tablet’s manufacturability and sublingual performance.
• The strongest excipient opportunities involve co-processed systems, taste masking, moisture control, and blend-uniformity technology.
• Generic entry depends on patent clearance, ANDA approval, controlled-substance infrastructure, and TIRF REMS compliance.
• The patent estate is more likely to derive strength from formulation, performance, and manufacturing claims than from fentanyl chemistry.
• Direct competition comes from other rapid-onset fentanyl products, while indirect competition includes nasal, buccal, transmucosal, and transdermal dosage forms.
• Commodity excipient substitution has limited commercial value unless it improves dose uniformity, stability, disintegration, or manufacturing economics.

FAQs

Can a generic ABSTRAL use different excipients?

Yes. A generic applicant may use different inactive ingredients if the product meets FDA requirements for pharmaceutical equivalence, performance, bioequivalence, safety, and labeling.

Is mannitol essential to ABSTRAL?

Mannitol is an important formulation component identified in product information, but it is not inherently required for every fentanyl sublingual tablet. A substitute must preserve mouthfeel, compression, stability, disintegration, and drug-release performance.

Can taste masking create a new patent opportunity for fentanyl sublingual tablets?

Yes. A specific coating, complexation system, particle architecture, or manufacturing process may support patent claims if it provides a technically demonstrated benefit and satisfies patentability requirements.

Does ABSTRAL have biosimilar risk?

No. ABSTRAL contains fentanyl citrate, a chemically synthesized small-molecule active ingredient. The relevant competitive pathway is generic substitution, not biosimilar approval.

What is the main manufacturing barrier for an ABSTRAL-like product?

The main barrier is consistent content uniformity at microgram active-ingredient levels while maintaining rapid disintegration, low friability, acceptable taste, stability, and controlled-substance security.

References

1. U.S. Food and Drug Administration. (2011). ABSTRAL (fentanyl citrate) sublingual tablets: Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022510s000lbl.pdf

2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: ABSTRAL, NDA 022510. https://www.accessdata.fda.gov/scripts/cder/daf/

3. U.S. Food and Drug Administration. (n.d.). Transmucosal immediate-release fentanyl products risk evaluation and mitigation strategy. https://www.accessdata.fda.gov/drugsatfda_docs/rems/TIRF_2011-12-28_REMS.pdf

4. Kyowa Kirin Co., Ltd. (2011). Kyowa Hakko Kirin acquires ProStrakan Group plc. https://www.kyowakirin.com/ir/news/2011/pdf/e20110222_01.pdf